Supplementary Table S1. Patient characteristics (sensitivity analysis)

	Overall (N=735)	HD group (N=333)	LDa group (N=54)	LDb group (N=24)	No-ASA group (N=324)	*P*-value
Background						
Age	2 (1–3)	2 (1–3)	2 (1–3.75)	1 (1–2)	2 (1–3)	0.52
Male sex	432 (58.8%)	200 (60.1%)	35 (64.8%)	13 (54.2%)	184 (56.8%)	0.62
Kobayashi score	3 (1–4)	3 (1–5)	4 (2–5)	4 (2.75–6)	2 (1–4)	<0.001
Predicted as IVIG non-responder	165 (22.4%)	85 (25.5%)	18 (33.3%)	8 (33.3%)	54 (16.7%)	<0.001
Clinical day of IVIG	5 (5–6)	5 (4–6)	5 (5–6)	5 (4–5.25)	5 (5–6)	0.005
Duration from onset to afebrile	6 (5–7)	6 (5–7)	7 (5–8)	5 (5–6)	5 (5–6)	0.004
Duration from treatment to afebrile	1 (1–2)	2 (1–2)	2 (1–2)	1 (1–2)	1 (1–2)	<0.001
Second-line Treatment						
Add second-line treatment	168 (22.9%)	78 (23.4%)	28 (51.9%)	7 (29.2%)	55 (17%)	<0.001
Second-line treatment						<0.001
IVIG+PSL	21 (12.5%)	4 (5.1%)	3 (10.7%)	0 (0.0%)	14 (25.4%)	
IVIG only	141 (83.9%)	72 (92.3%)	25 (89.3%)	6 (85.7%)	38 (69.1%)	
PSL only	3 (1.8%)	2 (2.6%)	0 (0.0%)	0 (0.0%)	1 (1.8%)	
Coronary Artery Lesions (CALs)						
CALs within 1 month (>+2.5 SD)	28 (3.8%)	12 (3.6%)	13 (24.0%)	1 (4.1%)	2 (0.6%)	<0.001
CALs within 1 month (5–<10 SD)	7 (1.0%)	4 (1.2%)	3 (5.6%)	0 (0.0%)	0 (0.0%)	<0.001
CALs within 1 month (>=10 SD)	2 (0.3%)	0 (0.0%)	1 (1.9%)	0 (0.0%)	1 (0.3%)	<0.001
CALs over 1 month (>+2.5 SD)	10 (1.4%)	6 (1.8%)	4 (7.4%)	0 (0.0%)	0 (0.0%)	<0.001
CALs over 1 year (>+2.5 SD)	2 (0.3%)	0 (0.0%)	2 (3.7%)	0 (0.0%)	0 (0.0%)	<0.001
Complications other than CALs						
ALT elevation	34 (4.6%)	10 (3.0%)	4 (7.4%)	1 (4.2%)	19 (5.9%)	0.25
Gall bladder swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	>0.99

Gastrointestinal ulcer	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	>0.99
Arthritis	3 (0.4%)	1 (0.3%)	2 (3.7%)	0 (0.0%)	0 (0.0%)	0.001
Seizure	6 (0.8%)	2 (0.6%)	1 (1.9%)	0 (0.0%)	3 (0.9%)	0.76
Facial nerve palsy	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	>0.99
Carditis	1 (0.1%)	0 (0.0%)	1 (1.9%)	0 (0.0%)	0 (0.0%)	0.006
ALT elevation within 2 months	2 (0.3%)	1 (0.3%)	1 (1.9%)	0 (0.0%)	0 (0.0%)	0.12
Laboratory findings						
White blood cell (10^9/L)	13.4 (10.5–16.6)	13.95 (11.3–17)	11.45 (8.85–14.75)	13.5 (11.18–17.1)	13.1 (10.2–16.4)	0.005
Percentage Neutrophil count	67.3 (57–77)	67.5 (58.35–77.18)	71 (63.5–81)	68 (59.5–87)	66 (53–76)	0.022
Haematocrit	33.9 (32.1–35.7)	34.15 (32.1–35.92)	34.1 (31.8–35.8)	33.75 (32.18–36.18)	33.8 (32.18–35.4)	0.80
Platelet count (10^9/L)	341 (277–402)	345 (284–400)	327 (263–419)	322 (279.5–397)	341 (276.7–406)	0.81
Albumin (g/dL)	3.6 (3.3–3.8)	3.6 (3.3–3.8)	3.4 (3.1–3.8)	3.65 (3.1–3.73)	3.5 (3.3–3.8)	0.17
C-reactive protein (mg/dL)	7.3 (4.4–11.2)	7.6 (4.7–11)	8.8 (5–12.25)	6.45 (4.45–12.6)	7.1 (3.68–11)	0.32
AST (IU/L)	35 (26–59)	33 (25–59)	37 (28–153.3)	81 (51.25–253)	34 (26–50)	<0.001
ALT (IU/L)	22 (12–87.5)	23 (13–83)	49.5 (14–184.5)	136.5 (69.5–269.5)	19 (12–60.5)	<0.001
Total bilirubin (mg/dL)	0.5 (0.4–0.8)	0.5 (0.4–0.8)	0.6 (0.5–1.2)	0.65 (0.48–1.12)	0.5 (0.4–0.7)	0.001
Serum Na (mEq/L)	135 (133–136)	134 (132–136	134 (132–136)	135 (132–136)	135 (133–137)	0.012

Data are presented as median (IQR) or number (percentage).

HD, high-dose acetylsalicylic acid; LDa, low-dose acetylsalicylic acid after IVIG; LDb, low-dose acetylsalicylic acid before IVIG; No-ASA, no acetylsalicylic acid

IVIG, intravenous immunoglobulin; PSL, prednisolone; ALT, aspartate aminotransferase; AST, aspartate aminotransferase; SD, standard deviation

Supplementary Table S2. Results of multivariate analysis for developing CALs within 1 month (sensitivity analysis)

	Unadjusted		Adjusted	
	Risk ratio (95% CI)	*P*-value	Risk ratio (95% CI)	*P*-value
HD	(reference)		(reference)	
LDa	7.63 (4.78–12.2)	<0.001	5.20 (2.83–9.55)	<0.001
LDb	1.64 (0.15–2.34)	0.007	0.86 (0.68–1.10)	0.23
No-ASA	0.20 (0.09–0.41)	<0.001	0.20 (0.10–0.39)	<0.001
Age (year)	–		0.43 (0.31–0.60)	<0.001
Male	–		0.90 (0.65–1.24)	0.51
Clinical day of IVIG	–		1.38 (1.13–1.67)	0.001
serum Na (mEq/L)	–		1.00 (0.97–1.24)	0.51
AST (IU/L)	–		1.00 (1.00–1.00)	0.002
%Neutrophil	–		1.04 (1.03–1.06)	<0.001
Platelet count (10^9/L)	–		1.00 (0.99–1.00)	0.03
C-reactive protein (mg/dL)	–		1.01 (0.97–1.04)	0.71

HD, high-dose acetylsalicylic acid; LDa, low-dose acetylsalicylic acid after IVIG; LDb, low-dose acetylsalicylic acid before IVIG

No-ASA, no acetylsalicylic acid; IVIG, intravenous immunoglobulin; AST, aspartate aminotransferase

Supplementary Table S3. Results of the multivariate analysis for IVIG unresponsiveness (sensitivity analysis)

	Unadjusted		Adjusted	
	Risk ratio (95% CI)	*P*-value	Risk ratio (95% CI)	*P*-value
HD	(reference)		(reference)	
LDa	2.42 (2.17–2.71)	<0.001	1.96 (1.76–2.19)	<0.001
LDb	1.69 (1.34–2.13)	<0.001	1.36 (1.04–1.78)	0.024
No-ASA	0.78 (0.58–1.05)	0.10	0.89 (0.66–1.21)	0.46
Age (year)	–		1.04 (0.99–1.10)	0.10
Male	–		1.19 (1.04–1.37)	0.011
Clinical day of IVIG	–		0.81 (0.71–0.91)	<0.001
serum Na (mEq/L)	–		0.95 (0.92–0.98)	0.005
AST (IU/L)	–		1.00 (1.00–1.01)	<0.001
%Neutrophil	–		1.02 (1.01–1.03)	0.002
Platelet count (10^9/ L)	–		1.00 (1.00–1.00)	<0.001
C-reactive protein (mg/dL)	–		1.02 (1.01–1.04)	<0.001

HD, high-dose acetylsalicylic acid; LDa, low-dose acetylsalicylic acid after IVIG; LDb, low-dose acetylsalicylic acid before IVIG

No-ASA, no acetylsalicylic acid; IVIG, intravenous immunoglobulin; AST, aspartate aminotransferase